摘要
目的评价131I美妥昔单抗注射液(利卡汀)联合TACE治疗中晚期原发性肝癌的疗效及安全性。方法收集2010年11月至2013年5月期间收治的76例原发性肝癌患者,按治疗意愿分为单抗组(美妥昔单抗联合TACE治疗)及对照组(单纯TACE治疗)各38例。入组患者按要求行介入治疗,并定期随访,以评估疗效及不良反应。随访截止日期为2015年3月或肿瘤出现进展。结果单抗组与对照组相比:1个月临床缓解率分别为23.7%和18.4%;疾病控制率分别为92.1%及97.4%;疾病中位无进展生存期(m PFS)为6个月及8个月,两组间差异无统计学意义(P>0.05)。两组间治疗相关的不良反应基本相仿,而在血液毒性及肝功能损害方面,试验组较对照组更为明显,但多为一过性,未发生与治疗药物相关的严重不良事件。结论对于中晚期原发性肝癌,美妥昔单抗联合TACE治疗安全性高,但疗效尚需进一步验证。
Objective To evaluate the efficacy and safety of 131I- labeled metuximab （Licartin） combined with transcatheter arterial chemoembolization （TACE） in treating advanced primary hepatic carcinomas. Methods A total of 76 patients with advanced primary hepatic carcinoma, who were admitted to authors＇ hospital during the period from November 2010 to May 2013, were enrolled in this study. According to patient＇s own will, the patients were divided into the study group （n=38,using 131I-labeled metuximab and TACE） and the control group （n=38, using TACE only）. All patients underwent the scheduled interventional therapy, and were regularly followed up to evaluate the therapeutic response and side-effects. The deadline for follow-up was March 2015 or the time when the tumor showed progress. Results The one- month clinical remission rates of the study group and the control group were 23.7% and 18.4% respectively, and the one-month disease control rates were 92.1% and 97.4% respectively; the median progress-free survival times of the study group and the control group were 6 months and 8 months respectively, the differences between the two groups were not statistically significant （P〉0.05）. The treatment-related adverse reactions of the two groups were basically similar; the hematological toxicity and liver function damage were more obvious in the study group than in the control group although most of them were transient; no drug-related severe adverse events occurred. Conclusion For the treatment of advanced primary hepatic carcinoma, 131I-labeled metuximab combined with TACE is highly safe, although its effectiveness needs to be further verified.
出处
《介入放射学杂志》
CSCD
北大核心
2016年第1期65-69,共5页
Journal of Interventional Radiology
基金
浙江医学高等专科学校科研项目(2008XZB02)
浙江省高层次创新人才培养工程基金(浙卫发2012-241号)
关键词
原发性肝癌:经肝动脉化疗栓塞术
131I美妥昔单抗
primary hepatic carcinoma
transcatheter arterial chemoembolization
131I - labeledmetuximab
